Keywords: merck, kgaa, discontinues, sarizotan, after, drug, misses

Merck KGAA discontinues sarizotan after drug misses Ph III efficacy endpoints in PADDY-1/2

Article | 03 July 2006

Print This

German drugmaker Merck KGaA says it will discontinue the development of its drug candidate sarizotan after it failed to demonstrate ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in